Growth Metrics

Supernus Pharmaceuticals (SUPN) Shares Outstanding (Weighted Average) (2016 - 2026)

Supernus Pharmaceuticals has reported Shares Outstanding (Weighted Average) over the past 15 years, most recently at $56.5 million for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 2.45% to $56.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $56.5 million through Dec 2025, up 2.45% year-over-year, with the annual reading at $56.5 million for FY2025, 2.45% up from the prior year.
  • Shares Outstanding (Weighted Average) was $56.5 million for Q4 2025 at Supernus Pharmaceuticals, up from $56.1 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $56.5 million in Q4 2025 and troughed at $52.9 million in Q1 2021.
  • The 5-year median for Shares Outstanding (Weighted Average) is $54.5 million (2023), against an average of $54.4 million.
  • Year-over-year, Shares Outstanding (Weighted Average) grew 0.7% in 2022 and then rose 2.45% in 2025.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $53.1 million in 2021, then grew by 1.07% to $53.7 million in 2022, then increased by 1.62% to $54.5 million in 2023, then increased by 1.03% to $55.1 million in 2024, then rose by 2.45% to $56.5 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Shares Outstanding (Weighted Average) are $56.5 million (Q4 2025), $56.1 million (Q3 2025), and $55.9 million (Q2 2025).